Eleva is a clinical-stage biopharmaceutical company unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform. The company’s proprietary drug development activities currently focus on complement disorders and enzyme replacement therapies. Factor H (CPV-104), a recombinant version of human complement Factor H, is expected to enter clinical studies in C3 Glomerulopathy (C3G) in H1 2025. The company’s aGal (RPV-001) program to treat Fabry disease has completed a Phase 1b clinical study with promising results. All programs are sourced from Eleva’s transformative moss-based expression system, which allows lab to GMP-scale manufacturing of challenging proteins with previously untapped therapeutic potential.
Company Details
- Employees
- 80
- Founded
- -
- Address
- Hans-Bunte-Str. 19, Freiburg,deutschland (Deu) 79108,germany
- Phone
- +49 761 470 99 0
- he****@****ics.com
- Industry
- Biotechnology
- Website
- elevabiologics.com
- Keywords
- Clinical Assets, Biopharmaceuticals, Biotechnology, Faktor H, Complement System, Alphagalactosidase, C3G, Morbus Fabry, Fabry Disease, Rare Diseases, C3 Glomerulopathy, Renal Diseases.
- HQ
- Freiburg, Deutschland (DEU)
Eleva Questions
Eleva's helpline number is +49 761 470 99 0
Eleva's website is elevabiologics.com
Eleva's LinkedIn profile is https://de.linkedin.com/company/eleva-gmbh
Eleva has
80 employees.
View email and phone details for 80
employees at Eleva.
Eleva's industry is
Biotechnology
Eleva's top competitors are
Bayer,
Crs Clinical Research Services,
Pixelbiosciences,
Eleva Facilities,
Biontech Se,
Molsid,
3p Biopharmaceuticals,
Mallia,
3pbiovian,
Eleva Group.
Eleva's support email address is hello@elevabiologics.com
Eleva's categories are Biotechnology
Eleva's founding year is 1999
